Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

Navigating Your Treatment: Strategies for HCC

At a Glance

Hepatocellular carcinoma (HCC) treatment is based on your BCLC stage and liver health. Early-stage options aim for a cure using surgery, transplant, or ablation. Intermediate to advanced stages focus on tumor control and survival using targeted liver therapies (TACE) or modern immunotherapies.

Treating Hepatocellular Carcinoma (HCC) is a highly specialized process that depends on two factors: the extent of the cancer and the underlying health of your liver [1]. Because modern treatments are advancing rapidly, it is important to ensure your care follows the most current evidence-based guidelines.

Treatment by BCLC Stage

The Barcelona Clinic Liver Cancer (BCLC) system guides your treatment pathway [2]. Below is the standard-of-care approach for each stage:

BCLC Stage Standard First-Line Treatment Goal
0 & A (Early) Surgical Resection, Liver Transplant, or Ablation Curative: Aiming to eliminate the cancer entirely [1][3].
B (Intermediate) TACE (Direct-to-liver chemotherapy) or Systemic Therapy Control: Slowing growth or shrinking the tumor [4][5].
C (Advanced) Systemic Therapy (Immunotherapy combinations) Extension: Improving survival and maintaining quality of life [6][7].
D (End-Stage) Best Supportive Care Comfort: Managing symptoms when the liver is too weak for treatment [2].

Early Stage: Resection vs. Transplant

If your cancer is caught early, you may have multiple options.

  • Resection: Surgical removal of the tumor is a durable option if your liver function is preserved and you do not have significant portal hypertension (high pressure in the liver’s veins) [8].
  • Liver Transplant: This is often preferred over resection if you have underlying cirrhosis, as it treats both the cancer and the failing liver [9][10]. Doctors use the Milan Criteria (one tumor <5cm or up to three tumors <3cm) to determine if a transplant is likely to be successful [11].
  • Ablation: Using heat (radiofrequency) or cold (cryotherapy) to destroy small tumors is a highly effective, less invasive alternative for very early tumors [1].

Advanced Stage: The New Standard of Care

The treatment for advanced HCC has changed significantly. In the past, a drug called Sorafenib was the only option. Today, combination therapies are the first-line standard for patients with good liver function (Child-Pugh A) [12][13]:

  • Atezolizumab + Bevacizumab: This combination of an immunotherapy and a drug that blocks blood vessel growth has shown superior survival compared to older treatments [6][14].
    • CRITICAL SAFETY STEP: Bevacizumab carries a severe risk of gastrointestinal bleeding. In patients with cirrhosis, enlarged veins in the esophagus (varices) can rupture and cause fatal bleeds. Guidelines mandate that you must have an upper endoscopy (EGD) to screen for and treat varices before starting this drug regimen [15][16].
  • STRIDE Regimen (Durvalumab + Tremelimumab): An immunotherapy-only combination that is an important option, especially for patients who cannot take bevacizumab due to a risk of bleeding [17][18].

Avoiding Treatment Pitfalls

In a rapidly changing field, some approaches have become outdated or may be used incorrectly:

  • TACE Overuse: A common error is continuing TACE treatments after the tumor has stopped responding (TACE-refractoriness). Current guidelines recommend transitioning to systemic therapy early if TACE is no longer effective [19][20].
  • Sorafenib as First Choice: While sorafenib is still used, it is no longer the preferred first-line treatment if a patient is eligible for newer immunotherapy combinations [13][21].
  • Ignoring Liver Function: Treatments like Atezolizumab + Bevacizumab require a “Child-Pugh A” liver score. Using these potent drugs in a “Child-Pugh B” or “C” liver can be dangerous [22].

The Role of Clinical Trials

Clinical trials are not a “last resort.” They are essential for accessing the next generation of therapies, such as combining immunotherapy with local treatments like TACE or radiation [23][24]. Joining a trial can provide access to novel treatments that are showing promise in improving long-term outcomes [25].

Common questions in this guide

How is the best treatment for my liver cancer determined?
Hepatocellular carcinoma treatment is guided by the BCLC staging system, which considers both the extent of your cancer and your underlying liver health. Options range from curative surgeries for early stages to targeted drugs for advanced disease.
Is a liver transplant better than tumor removal surgery for HCC?
A liver transplant is often preferred over surgical tumor removal if you also have underlying liver cirrhosis. A transplant treats both the cancer and the failing liver simultaneously, though you must meet specific criteria regarding tumor size and number to qualify.
What are the newest treatments for advanced HCC?
The standard of care for advanced HCC now involves combination immunotherapies, such as Atezolizumab plus Bevacizumab or the STRIDE regimen. These combination treatments have shown superior survival rates compared to older therapies.
Why do I need an endoscopy before starting Atezolizumab and Bevacizumab?
Bevacizumab carries a severe risk of gastrointestinal bleeding, which can be fatal if you have enlarged veins in your esophagus. An upper endoscopy is mandatory to screen for and treat these enlarged veins before you can safely start this medication.
When should TACE treatment for liver cancer be stopped?
TACE should be stopped if the liver tumor is no longer responding to the procedure. Current medical guidelines recommend transitioning to systemic medications early rather than continuing TACE once it becomes ineffective.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my BCLC stage, why is the proposed treatment the best first-line option for me?
  2. 2.If I am a candidate for surgery, would a liver transplant provide a better long-term survival outcome than resection?
  3. 3.If we are considering Atezolizumab + Bevacizumab, when will I be scheduled for an upper endoscopy to check for varices?
  4. 4.If we are planning for TACE, how will we know if it is time to stop and switch to systemic therapy?
  5. 5.Are there any clinical trials evaluating immunotherapy combinations or new locoregional treatments that I qualify for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Benson AB, D'Angelica MI, Abbott DE, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

    PMID: 34030131
  2. 2

    BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

    Reig M, Sanduzzi-Zamparelli M, Forner A, et al.

    Journal of hepatology 2026; (84(3)):631-654 doi:10.1016/j.jhep.2025.10.020.

    PMID: 41151697
  3. 3

    Hepatocellular Carcinoma-How to Determine Therapeutic Options.

    Mehta N

    Hepatology communications 2020; (4(3)):342-354 doi:10.1002/hep4.1481.

    PMID: 32140653
  4. 4

    Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.

    Ai H, Gong T, Ma Y, et al.

    Frontiers in immunology 2024; (15()):1358602 doi:10.3389/fimmu.2024.1358602.

    PMID: 38863699
  5. 5

    Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.

    Rimini M, Stefanini B, Tada T, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(5)):1108-1125 doi:10.1111/liv.15885.

    PMID: 38517286
  6. 6

    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

    Finn RS, Qin S, Ikeda M, et al.

    The New England journal of medicine 2020; (382(20)):1894-1905 doi:10.1056/NEJMoa1915745.

    PMID: 32402160
  7. 7

    Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.

    Ahmed Z, Lee SS, Victor DW, Kodali S

    Journal of hepatocellular carcinoma 2023; (10()):1911-1922 doi:10.2147/JHC.S395080.

    PMID: 37915617
  8. 8

    Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis.

    Hasjim BJ, Paukner M, Kwong AJ, et al.

    Transplantation 2026; (110(1)):e204-e216 doi:10.1097/TP.0000000000005536.

    PMID: 41082247
  9. 9

    Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function.

    Liu JB, Baker TB, Suss NR, et al.

    Surgery 2017; (162(5)):1032-1039 doi:10.1016/j.surg.2017.07.017.

    PMID: 28866312
  10. 10

    Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.

    Benjamin AJ, Baker TB, Talamonti MS, et al.

    Surgery 2018; (163(3)):582-586 doi:10.1016/j.surg.2017.12.005.

    PMID: 29370929
  11. 11

    The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.

    Sapisochin G, Goldaracena N, Laurence JM, et al.

    Hepatology (Baltimore, Md.) 2016; (64(6)):2077-2088 doi:10.1002/hep.28643.

    PMID: 27178646
  12. 12

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

    Cheng AL, Qin S, Ikeda M, et al.

    Journal of hepatology 2022; (76(4)):862-873 doi:10.1016/j.jhep.2021.11.030.

    PMID: 34902530
  13. 13

    Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic agents compared to sorafenib or lenvatinib in the treatment of unresectable or advanced hepatocellular carcinoma a pairwise meta-analysis of randomized controlled trials.

    Liu Z, Jiang Y, Deng Y, Liu J

    International journal of surgery (London, England) 2025; doi:10.1097/JS9.0000000000004156.

    PMID: 41342522
  14. 14

    Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?

    Himmelsbach V, Koch C, Trojan J, Finkelmeier F

    Journal of hepatocellular carcinoma 2024; (11()):363-372 doi:10.2147/JHC.S443218.

    PMID: 38405324
  15. 15

    Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.

    Salem R, Li D, Sommer N, et al.

    Cancer medicine 2021; (10(16)):5437-5447 doi:10.1002/cam4.4090.

    PMID: 34189869
  16. 16

    Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.

    Feng JK, Liu ZH, Fu ZG, et al.

    Frontiers in oncology 2022; (12()):954203 doi:10.3389/fonc.2022.954203.

    PMID: 36505818
  17. 17

    Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective.

    Ikeda M, Morizane C, Ueno M, et al.

    Japanese journal of clinical oncology 2025; (55(5)):465-476 doi:10.1093/jjco/hyaf017.

    PMID: 39895083
  18. 18

    Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

    Song X, Kelley RK, Khan AA, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(4)):754-763 doi:10.1158/1078-0432.CCR-22-1983.

    PMID: 36477555
  19. 19

    Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.

    Su TH, Wu CH, Liu TH, et al.

    Clinical and molecular hepatology 2023; (29(2)):230-241 doi:10.3350/cmh.2022.0421.

    PMID: 36710607
  20. 20

    Switching to systemic therapy after locoregional treatment failure: Definition and best timing.

    Ogasawara S, Ooka Y, Koroki K, et al.

    Clinical and molecular hepatology 2020; (26(2)):155-162 doi:10.3350/cmh.2019.0021n.

    PMID: 31937081
  21. 21

    A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.

    Awosika J, Sohal D

    Journal of gastrointestinal oncology 2022; (13(1)):426-437 doi:10.21037/jgo-21-274.

    PMID: 35284102
  22. 22

    Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab.

    Ledenko M, Mercado L, Patel T

    American journal of clinical oncology 2024; (47(3)):105-109 doi:10.1097/COC.0000000000001067.

    PMID: 38047447
  23. 23

    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

    Yau T, Galle PR, Decaens T, et al.

    Lancet (London, England) 2025; (405(10492)):1851-1864 doi:10.1016/S0140-6736(25)00403-9.

    PMID: 40349714
  24. 24

    Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

    Werner W, Kuzminskaya M, Lurje I, et al.

    Seminars in liver disease 2024; (44(2)):159-179 doi:10.1055/a-2334-8311.

    PMID: 38806159
  25. 25

    Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma.

    Gok Yavuz B, Hasanov E, Lee SS, et al.

    Journal of hepatocellular carcinoma 2021; (8()):1195-1207 doi:10.2147/JHC.S322289.

    PMID: 34595140

This page provides educational information on hepatocellular carcinoma (HCC) treatments. It does not replace professional medical advice. Always discuss your specific treatment plan and BCLC stage with your multidisciplinary liver cancer care team.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.